AstraZeneca pauses two cancer drug trials' enrolment due to bleeding

LONDON (Reuters) - AstraZeneca's high hopes for cancer immunotherapy were dented on Thursday as the recruitment of new patients with head and neck cancer into two clinical studies was put on hold, following instances of bleeding.